As shown in Table 2, thoracic perfusion of cisplatin down-regulated the Hsp90-beta level in MPE of lung cancer patients (2.01 ± 0.66 ng/mL versus 1.82 ± 0.23 ng/mL) (P < 0.001) (Fig. 1c). The gene discussed is HSP90AB1; the disease is lung cancer.